Akums Drugs & Pharmaceuticals Share Price Target 2025, 2026, 2030, 2040, 2050

Akums Drugs & Pharmaceuticals Ltd is an Indian company that helps other businesses create and make medicines. They offer many services, including developing new drugs, manufacturing them, and helping with approvals from health authorities. It works with companies in areas like pharmaceuticals, supplements, cosmetics, and herbal products all over the world. They have advanced factories that can make a variety of products, such as pills, liquids, and injections. The company is known for its global reach and high-quality standards, with certifications from top health organisations.

What is Akums Drugs & Pharmaceuticals Ltd. NSE: AKUMS?

Akums Drugs & Pharmaceuticals is a major Indian company that makes medicines for other companies, a type of contract manufacturer. It was started in 2004 by two brothers, Sanjeev and Sandeep Jain, and is situated in Delhi. It has 12 factories and 4 research centres where it makes different kinds of products like regular medicines, health supplements, herbal items, and skincare products. It sells these products in over 50 countries and has special approvals like EU-GMP for quality. It also does social work, helping in areas like health, education, the environment, and during the COVID-19 pandemic.

Share Price Target Tomorrow

After listening to the stock market, it shows a good bullish move, but after reaching a point, the stock has shown a very strong bearish move. At the current time, the stock is starting to recover at a very slow rate. The bullish move is not so strong as it fell. For buying the stock, wait for multiple confirmations and a strong bullish trend.

Day	Minimum Price (Rs)	Maximum Price (Rs)
Tomorrow	-17	+30

Akums Drugs share price Target 2025

It is the largest company in India that helps other pharmaceutical companies develop and make medicines. It plays an important role in improving healthcare in the Indian Pharmaceutical Market. It has made over 4,100 approved medicines in more than 60 different forms, covering many health areas like heart and diabetes care, brain and nerve health, women’s health, kidney care, infections, breathing problems, pain relief, and vitamins. In 2025, its share price target would be ₹1342, as per our analysis.

By our prediction, its share price would be between ₹275 to ₹1342 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	275	1342

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	526	652
February	445	618
March	432	530
April	400	544
May	490	630
June	425	700
July	344	774
August	275	800
September	452	985
October	651	1058
November	845	1254
December	1125	1342

Akums Drugs Share Price Target 2026

The company is doing well by making medicines for other companies. It has made good profits recently and has paid off most of its debt, which is a positive sign. The company’s stock price is higher than the value of its assets, which shows people expect it to grow more. Its profit compared to the money invested is good, but not very high compared to other companies like it. Overall, it is growing steadily and handling its money carefully, but it needs to increase its sales and share more profits with its investors. In 2026, its share price target would be ₹2240, as per our analysis.

By our prediction, its share price would be between ₹1125 to ₹2240 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1125	2240

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1125	1400
February	1225	1435
March	1285	1474
April	1352	1500
May	1384	1562
June	1425	1578
July	1458	1600
August	1490	1756
September	1568	1856
October	1684	1958
November	1856	2157
December	2044	2240

Share price Target 2027

They offer many services like creating new drug formulas, testing how the body reacts to them, doing clinical trials, and helping get approval from the government. They are especially good at getting permission for new drug mixes and special types of medicines from India’s drug authority. The company uses modern technology to make medicines that fit what each customer needs. The company is known for its focus on quality, new ideas, and being trustworthy. In 2027, its share price target would be ₹3120, as per our prediction.

Its share price would be between ₹2044 to ₹3120 in 2027, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	2044	3120

Share price Target 2028

The company focuses on new ideas and always maintains its quality. It uses better tools and methods to improve how medicines are made. The goal is to make sure every product is safe, effective, and meets high standards. A hardworking and skilled team helps improve current products and also creates new ones through research. This strong focus on quality and innovation helps meet the needs of customers, partners, workers, and the community. In 2028, its share price target would be ₹3942, as per our analysis.

By our prediction, its share price would be between ₹3002 to ₹3942 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	3002	3942

Share price Target 2029

The company has several modern factories to make many different high-quality products. It is always trying to find new ideas and improve products through research and development. By thinking creatively and using advanced ways to make products, the company has built a wide variety of products that meet many different needs. Because of this focus on quality and new ideas, the company is known and trusted in the industry. In 2029, its share price target would be ₹4752, as per our prediction.

Its share price would be between ₹3800 to ₹4752 in 2029, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	3800	4752

Akums Drugs share price Target 2030

The company is a pharmaceutical contract development and manufacturing organisation that provides many types of medicine products and services in India and other countries. It is one of the top CDMOs and owns the rights to make several medicines. It also does research to create new medicines, prepares important documents to get approval for selling medicines in India and abroad, and performs different tests to ensure quality. The company offers many different medicines in various forms and works in many countries. It focuses on research and makes sure all products are safe and work well through careful quality checks. In 2030, its share price target would be ₹5585, as per our analysis.

By our prediction, its share price would be between ₹4600 to ₹5585 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	4600	5585

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4600	4868
February	4758	4988
March	4790	5000
April	4865	5041
May	4958	5100
June	5084	5231
July	5124	5265
August	5165	5290
September	5221	5314
October	5258	5424
November	5322	5541
December	5400	5585

Share price Target 2040

It offers complete and personalised medicine services for different health needs through its research, development, testing, large-scale production, and obtaining necessary approvals. The company follows all safety rules and keeps working on new and better medicines to help people live healthier lives. As part of this effort, it has launched a new capsule with a mix of Tamsulosin and Tadalafil, made to help people feel better and live a good life, with prostate problems and trouble getting an erection. In 2040, its share price target would be ₹10960, as per our prediction.

Its share price would be between ₹10060 to ₹10960 in 2040, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	10060	10960

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	10060	10195
February	10099	10235
March	10142	10300
April	10184	10354
May	10232	10425
June	10284	10486
July	10300	10523
August	10325	10584
September	10375	10600
October	10458	10745
November	10568	10854
December	10690	10960

Share Price Target 2050

The company has strong expertise in chemistry and process development, which helps the company make many types of small molecule medicines, including special ones like Beta-lactams, Non Beta-lactams, HPAPIs, and both oral and injectable forms. These abilities help it to create medicines for important health problems like infections, diabetes, high blood pressure, stomach issues, cancer, and pain. The company is good at handling complex chemical steps, improving how medicines are made, and using advanced methods like checking different forms of substances, working with special types of chemicals, and using enzymes. In 2050, its share price target would be ₹17500, as per our analysis.

By our prediction, its share price would be between ₹16601 to ₹17500 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	16601	17500

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	16601	16852
February	16678	16900
March	16725	16951
April	16788	17000
May	16852	17125
June	16974	17235
July	17000	17354
August	17154	17420
September	17200	17584
October	17284	17632
November	17365	17700
December	17457	17788

Should I buy Akums Drugs stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	275	1342
2026	1125	2240
2027	2044	3120
2028	3002	3942
2029	3800	4752
2030	4600	5585
2040	10060	10960
2050	16601	17500

It is a strong company that makes medicines for other companies and sells them in many countries. It has paid off most of its loans and is starting to make more profit, which is a good sign. The company is known for good quality and new ideas. But recently, its sales and profits have gone down, it doesn’t give dividends to its investors, and the stock price is a little high. So, even though the company looks good for the future, it’s better to wait until it shows a good bullish trend before buying the stock.

Akums Drugs’ earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales +	2,414	2,723	3,672	3,655	4,178	4,118
Expenses +	2,240	2,485	3,761	3,361	4,055	3,654
Operating Profit	174	237	-89	294	123	464
OPM %	7%	9%	-2%	8%	3%	11%
Other Income +	26	12	7	15	8	69
Interest	20	7	17	46	51	35
Depreciation	67	70	95	113	126	153
Profit before tax	114	172	-193	150	-45	345
Tax %	62%	28%	30%	35%	-102%	0%
Net Profit +	44	123	-251	98	1	344
EPS in Rs	335.61	949.10	-35.30	6.63	-0.28	21.49
Dividend Payout %	0%	0%	0%	0%	0%	0%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
25.39	11.92	—	35.55	6.55	0.81%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Akums Drugs and Pharmaceuticals Ltd	25.39	11.92	—
Sun Pharmaceutical Industries Ltd	36.95	6.02	0.95%
Cipla Ltd	22.82	4.49	1.07%
Dr Reddy’s Laboratories Ltd	18.99	3.80	0.62%

Is Akum’s Drugs stock good to buy? (bull case & bear case)

Bull Case:

• Went from having ₹322 crore debt to ₹339 crore cash, very strong financially now
• Profit margins are improving, now making more profit for every ₹1 of sales
• Has reduced most of its debt
• Has grown profits at 49.2% per year over the last 5 years, a very strong performance
• It has grown its profits by about 49% per year over the last 5 years

Bear Case:

• Sales fell by 6% in the last quarter compared to a year ago
• Profit dropped by 66% in the last quarter — that’s a big fall
• Even though the company makes profits regularly, it doesn’t give any dividends to shareholders

Conclusion

It is a strong Indian company that makes medicines for other companies. It has paid off most of its loans and is known for good quality and working with many countries. The company is trying to grow and improve, which is a good sign. But recently, its sales and profits have gone down, and it doesn’t give any dividends. Also, the stock price may be a little high right now. So, while the company looks good for the future, it’s better to wait until it becomes more stable.

FAQs